menu
    • menu
    [{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Omeros","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"OMS527","moa":"PDE7","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Caamtech","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institute on Drug Abuse \/ Caamtech","highestDevelopmentStatusID":"1","companyTruncated":"National Institute on Drug Abuse \/ Caamtech"}]

    Find Clinical Drug Pipeline Developments & Deals by National Institute on Drug Abuse

    Menu

    National Institute on Drug Abuse

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            National Institute on Drug Abuse

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            National Institute on Drug Abuse

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OMS527

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Recipient : Omeros

                            Deal Size : $4.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Omeros Secures $4M from NIDA for OMS527 To Treat Cocaine Use Disorder

                            Details : The funding aims to support the OMS527 is an orally bioavailable, small molecule antagonist of PDE7. It is being evaluated to treat Cocaine Use Disorder.

                            Product Name : OMS527

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 13, 2025

                            Lead Product(s) : OMS527

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Recipient : Omeros

                            Deal Size : $4.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            National Institute on Drug Abuse

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            National Institute on Drug Abuse

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Psilocybine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Undisclosed

                            Sponsor : Caamtech

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            CaaMTech Collaborates With National Institutes of Health to Research Psychedelics

                            Details : The Designer Drug Research Unit at the National Institute on Drug Abuse will conduct research on CaaMTech's library of tryptamine-based compounds.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            July 05, 2020

                            Lead Product(s) : Psilocybine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Undisclosed

                            Sponsor : Caamtech

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth